MARKETSnap
  • Gainers &
    Losers
  • Most Active &
    More
  • 52-Week
    High/Low
  • P/E
    Ratios
    • Large Caps
    • Absolute
    • Total Market PE
  • Stocks
    Performance
    • Large Caps
    • Absolute
  • Industries
    Performance
    • Industry
    • Sector
  • Dividends
  • 📅 Calendar
    • Earnings Calendar
    • Dividends Calendar
    • Economics Calendar
  • 🔧 Tools
    • 💰 Intrinsic Value Calculator
    • 📈 Compounding Calculator
    • 🤖 Stock Pick Screener
  • More
    • Charts
    • Investment Compounding Calculator
    • Commodities
    • Currencies
    • Economic Indicators
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
CRON stock logo

CRON

Cronos Group Inc.

$3.35
-0.02
 (-0.59%)
Exchange:  NASDAQ
Market Cap:  1.252B
Shares Outstanding:  12.749M
Delayed data
Calculate CRON Intrinsic Value
5-year outlook →
Overview
Earnings
Financials
Valuation
Chart

About The Company

Sector:  HealthcareView sector performance
Industry:  Drug Manufacturers – Specialty & GenericView industry performance
   
CEO:  Michael Ryan Gorenstein
Full Time Employees:  610
Address: 
4491 Concession Road 12
Stayner
ON
L0M 1S0
CA
Website:  https://www.thecronosgroup.com
Cronos Group Inc. is a company primarily focused on cannabinoids. In the United States, it develops, promotes, and supplies hemp-derived wellness and beauty products under the Lord Jones and Happy Dance brands, reaching consumers through online sales, traditional retail outlets, and partnerships within the hospitality sector. Beyond hemp, the company also engages in the cultivation, production, and commercialization of cannabis and its related extracts for both therapeutic and recreational consumption. Its cannabis offerings encompass dried flower, pre-rolled joints, edibles, concentrates, and various extracts, which are distributed via wholesale channels and directly to clients. The wellness segment operates under the PEACE NATURALS platform, while its adult-use products are marketed through the Spinach brand. Additionally, Cronos exports dried cannabis and cannabis oils to international markets such as Germany, Israel, and Australia. Founded in 2012, the company’s headquarters are located in Toronto, Canada.

Click to read more…

Revenue Segmentation

MARKETSnap
MARKETSnap

Log in to continue

Log in to see the complete revenue and geographic breakdown.

Login — it's free

Industry Peers

TICKERCOMPANYMKT CAPP/EFWD P/EROIC
CRCRON logoCRONCronos Group Inc.1.3B16.629.30.0%
HRHROW logoHROWHarrow Health, Inc.1.2B——1.8%
PAPAHC logoPAHCPhibro Animal Health Corporation1.4B14.511.311.8%
AMAMPH logoAMPHAmphastar Pharmaceuticals, Inc.1.0B13.78.05.9%
ETETON logoETONEton Pharmaceuticals, Inc.1.5B12350.920.4%
PCPCRX logoPCRXPacira BioSciences, Inc.971.2M72.07.21.4%

EPS

Historical EPS and analyst estimates in one chart. Log in for the full interactive view and links to detailed estimates.

Log in to continue

Log in for the full EPS chart and links to analyst estimates.

Login — it's free
View full analyst estimates

Earnings Call

Full text

Earnings transcript

Read the complete earnings call transcript.

AI summary

Key takeaways

Short, structured highlights from the call so you can focus on what matters.

2026/08/06 — Q2 quarter 2026

Log in to continue

Log in to read the full transcript and AI-generated earnings summaries.

Login — it's free
Income Statement
Balance Sheet
Cash Flow Statement
Analyst Estimates

Income Statement

Year202320242025
Revenue87,241117,615149,153.083
Gross Profit11,90925,19861,701.535
EBITDA-71,800-50,213-3,358.786
Operating Income-84,800-76,529-17,838.907
Net Income-73,96341,080-9,612.374

Log in to continue

Log in to see the income statement and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Balance Sheet

Year202320242025
Total Assets1,140,0851,166,3121,197,140
Total Liabilities43,96155,33054,181
Total Stockholders Equity1,099,5711,064,0631,093,897
Total Debt2,5532,0181,509
Cash and Cash Equivalents669,291858,805791,794

Log in to continue

Log in to see the balance sheet and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Cash Flow Statement

Year202320242025
Operating Cash Flow-42,83518,8430
Capital Expenditure-3,423-12,4110
Free Cash Flow-46,2586,4320
Net Income-74,55340,0220
Net Change in Cash-95,353189,514-67,011

Log in to continue

Log in to see the cash flow statement and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Analyst Estimates

Fiscal Year2030Research AccessResearch AccessResearch AccessResearch Access
Estimated Revenue (Low)179,415.797Research AccessResearch AccessResearch AccessResearch Access
Estimated Revenue (High)225,893.505Research AccessResearch AccessResearch AccessResearch Access
Estimated Revenue (Avg)208,676Research AccessResearch AccessResearch AccessResearch Access
Estimated Ebitda (Low)80,226.418Research AccessResearch AccessResearch AccessResearch Access
Estimated Ebitda (High)101,058.537Research AccessResearch AccessResearch AccessResearch Access
Estimated Ebitda (Avg)93,342.781Research AccessResearch AccessResearch AccessResearch Access
Estimated Net Income (Low)53,561.416Research AccessResearch AccessResearch AccessResearch Access
Estimated Net Income (High)72,526.188Research AccessResearch AccessResearch AccessResearch Access
Estimated Net Income (Avg)65,502.056Research AccessResearch AccessResearch AccessResearch Access
Estimated SGA Expense (Low)181,359.881Research AccessResearch AccessResearch AccessResearch Access
Estimated SGA Expense (High)228,341.204Research AccessResearch AccessResearch AccessResearch Access
Estimated SGA Expense (Avg)210,937.137Research AccessResearch AccessResearch AccessResearch Access
Estimated EPS (Avg)0.170Research AccessResearch AccessResearch AccessResearch Access
Estimated EPS (High)0.190Research AccessResearch AccessResearch AccessResearch Access
Estimated EPS (Low)0.140Research AccessResearch AccessResearch AccessResearch Access
Number of Analysts (Estimated Revenue)2Research AccessResearch AccessResearch AccessResearch Access
Number of Analysts (Estimated EPS)1Research AccessResearch AccessResearch AccessResearch Access

Log in to continue

Log in and subscribe to Full Access to see up to 5 years of analyst estimates.

Login — it's free

(* All numbers are in thousands)

Current Key Metrics

?Revenue
 (TTM)
: 
111.968M  ?P/S
 (TTM)
: 
6.5
?Net Income
 (TTM)
: 
39.108M  ?P/E
 (TTM)
: 
16.59
?Enterprise Value
 (TTM)
: 
698.403M  ?EV/FCF
 (TTM)
: 
14.05
?Dividend Yield
 (TTM)
: 
0%  ?Payout Ratio
 (TTM)
: 
0%
?ROE
 (TTM)
: 
6.46%  ?ROIC
 (TTM)
: 
0.05%
?Net Debt
 (TTM)
: 
-856277366  ?Debt/Equity
 (TTM)
: 
0
?P/B
 (TTM)
: 
1.09  ?Current Ratio
 (TTM)
: 
16.18

Log in to continue

Log in to see all key valuation metrics and ratios for this symbol.

Login — it's free

Forward P/E Ratios

?

Forward P/E (Avg EPS estimate) — log in with Research Access for high/low estimates and the interactive table.

Forward P/E 1YResearch AccessResearch AccessResearch AccessResearch Access
29.30Research AccessResearch AccessResearch AccessResearch Access

Log in to continue

Log in with Full Access for forward P/E high/low estimates and the full multi-year table.

Login — it's free

SWOT Analysis

🔒 You are currently logged out

Login

It's free

At what price to buy it? -
Intrinsic Value Calculator

Based on current fundamentals and analyst forecasts, MARKETSnap estimates CRON intrinsic value between $0.25 – $0.73 per share. This depends on revenue growth, margins, and discount rate.

This is an automatic estimate. The most reliable way to know fair value for your own assumptions is to run the calculator below.

[intrinsic_calculator]

Common questions about CRON valuation

Is Cronos Group Inc. (CRON) overvalued or undervalued right now?

MARKETSnap estimates intrinsic value for Cronos Group Inc. (CRON) using its proprietary valuation methodology, which incorporates discounted cash flow (DCF) analysis together with long-term earnings and fundamentals assumptions. By comparing intrinsic value to the current market price, long-term investors can see whether the stock screens as potentially overvalued, fairly valued, or undervalued today.

Is CRON a buy, hold, or sell for long-term investors?

MARKETSnap does not give one-word “buy” or “sell” calls. Instead, it shows whether CRON trades at a premium or discount to its estimated intrinsic value, how sensitive that value is to growth and margin assumptions, and how the stock fits into a diversified, long-term portfolio so investors can make their own buy, hold, or sell decision.

What is CRON’s P/E ratio?

You can see CRON’s trailing P/E (TTM) and forward P/E estimates in the Current Key Metrics and Forward P/E Ratios sections above. The P/E ratio compares the current share price to earnings per share and helps investors gauge valuation relative to earnings.

How is intrinsic value calculated for CRON?

MARKETSnap uses its own valuation framework—not a generic spreadsheet DCF alone. Future cash flows and earnings are projected, discounted, and combined with MARKETSnap’s methodology so intrinsic value reflects fundamentals and long-term assumptions. You can run your own inputs and see the result using the Intrinsic Value Calculator above.

Is CRON a good long-term investment?

Whether CRON fits a long-term portfolio depends on your assumptions about growth, margins, and risk. MARKETSnap provides the metrics, intrinsic value calculator, and SWOT context so you can form your own view rather than rely on a single buy/sell rating.

CRON

1-day price chart preview. Log in for 1W through 5Y ranges and period tabs.

Daily snapshot

-0.59
MARKETSnap

Trading Metrics:

Open: 3.38   Previous Close: 3.37
Day Low: 3.34   Day High: 3.4
Year Low: 2.28   Year High: 3.61
Price Avg 50: 3.07   Price Avg 200: 2.77
Volume: 1.061M   Average Volume: 1.243M

Log in to continue

Log in for multi-period charts (1W–5Y), period tabs, and the same layout as members.

Login — it's free
See in Nexus

Relevant news

Cronos: Invest In Cannabis With 50% Net Cash And GAAP Profitability
15-09-2026 16:36
Cronos: Invest In Cannabis With 50% Net Cash And GAAP Profitability
Cronos to Host 2026 Investor Day at its Cronos GrowCo Facility in Kingsville, Ontario
15-09-2026 16:15
Cronos to Host 2026 Investor Day at its Cronos GrowCo Facility in Kingsville, Ontario
Surging Earnings Estimates Signal Upside for Cronos (CRON) Stock
18-08-2026 13:21
Surging Earnings Estimates Signal Upside for Cronos (CRON) Stock
Cronos Group: This Cannabis Name Isn't Reliant On U.S. Legalization Efforts
07-08-2026 13:33
Cronos Group: This Cannabis Name Isn't Reliant On U.S. Legalization Efforts
Cronos Announces Appointment of ATB Cormark as its Broker for Share Repurchases in Canada
30-06-2026 17:15
Cronos Announces Appointment of ATB Cormark as its Broker for Share Repurchases in Canada
CRON Strengthens Global Footprint: Is the Cannabis Stock Worth Buying?
24-06-2026 09:25
CRON Strengthens Global Footprint: Is the Cannabis Stock Worth Buying?

DISCLAIMER: The stock market data provided on this website is for informational purposes only and is not intended for trading purposes. While we strive to provide accurate and timely information, we cannot guarantee that the information is accurate at the moment it is received or that it will continue to be accurate in the future. We are not responsible for any actions taken based on the information provided on this website. Always consult with a licensed financial professional before making any investment decisions.
Terms of Service

Copyright © 2025 MarketSnap. All rights reserved.

Contact Us

Privacy Policy

Cookie Policy

Terms of Service

Hover Image
MARKETSnap

Market

🇺🇸 United States

Language

  • Gainers & Losers
  • Most Active & More
  • 52-Week High/Low
  • Dividends
    • Large Caps
    • Absolute
    • Total Market PE
    • Large Caps
    • Absolute
    • Industry
    • Sector
    • Earnings Calendar
    • Dividends Calendar
    • Economics Calendar
  • Learn
  • 💰 Stock intrinsic value Calculator
  • 📈 Investment Compounding Calculator
  • 🤖 Stock Pick Screener
  • 📋 Watchlist & Portfolio
    • Commodities
    • Currencies
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
  • Nexus
  • Login Login
  • Profile Profile
  • Watchlist & Portfolio Watchlist & Portfolio
  • My Valuations My Valuations
  • Settings Settings

Media

Watch Listen Read